Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix, Inivata to Develop NGS-based Lung Cancer MDx

NEW YORK (GenomeWeb) – Biodesix and Inivata today announced they will develop and commercialize next-generation sequencing-based blood tests for clinical applications in lung cancer. 

The deal will leverage Inivata's enhanced TAm-Seq technology and Biodesix's development and commercialization capabilities in theUSto provide new, clinically actionable tests to physicians. They will conduct studies in non-small cell lung cancer using Inivata's platform, and jointly fund studies to establish the clinical utility for an NGS-based test. They also will initiate an observational study later this year, they said. 

Financial and other terms of the deal were not disclosed. 

"The combination of our world-class blood-based sequencing technology with Biodesix’s ability to develop and establish diagnostics as standard of care creates a strong platform to develop new highly clinically relevant tests," Inivata CSO Nitzan Rosenfeld said in a statement.